Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €26.82 EUR
Change Today -0.245 / -0.91%
Volume 9.0K
BIO On Other Exchanges
Symbol
Exchange
Xetra
Xetra
OTC US
OTC US
OTC US
As of 10:15 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

biotest ag (BIO) Snapshot

Open
€27.50
Previous Close
€27.06
Day High
€27.50
Day Low
€26.63
52 Week High
03/16/15 - €35.30
52 Week Low
06/29/15 - €21.67
Market Cap
1.1B
Average Volume 10 Days
6.9K
EPS TTM
€0.39
Shares Outstanding
19.8M
EX-Date
05/8/15
P/E TM
68.0x
Dividend
€0.20
Dividend Yield
0.75%
Current Stock Chart for BIOTEST AG (BIO)

Related News

No related news articles were found.

biotest ag (BIO) Related Businessweek News

No Related Businessweek News Found

biotest ag (BIO) Details

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for the treatment of primary immune deficiency; Cytotect for cytomegalovirus (CMV) infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for the treatment of hepatitis B re-infection prophylaxis; Nabi-HB for post exposure prophylaxis; Intratect for primary immune and secondary antibody deficiency syndromes, as well as for autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; and Pentaglobin to treat bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat CMV infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for rheumatoid arthritis and psoriasis; Fibrinogen to treat fibrinogen deficiency; and IgM concentrate for the treatment of bacterial infections. It has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

2,188 Employees
Last Reported Date: 05/7/15
Founded in 1946

biotest ag (BIO) Top Compensated Officers

Chairman of the Board of Management and Chief...
Total Annual Compensation: €70.0K
Chief Financial Officer, Head of Finances & C...
Total Annual Compensation: €423.0K
Chief Operating Officer and Member of Board o...
Total Annual Compensation: €370.0K
Compensation as of Fiscal Year 2014.

biotest ag (BIO) Key Developments

Biotest Announces Encouraging Results from Phase II Pneumonia Trial

Biotest AG, has announced encouraging results from a Phase II trial with IgM enriched immunoglobulin preparation, or IgM Concentrate, in 160 hospitalized patients with severe community acquired pneumonia, or sCAP. This patient population has a high mortality rate and comprises severely ill patients which are in need of intensive care. The study was conducted in Germany, Spain and UK. After consulting experts and authorities, Biotest has chosen a new approach by using ventilator free days (VFDs) as primary endpoint taking into consideration that the relatively small sample size would not suffice to show significant differences in mortality. Therefore, 28-day mortality was selected as one of the secondary endpoints as recommended by the sepsis guideline of the European Medical Agency (EMA). The mortality rate in this indication is high, depending on age and treatment conditions. The severity of the disease in the treated patients was confirmed by validated disease severity scores. The treatment with IgM Concentrate showed a trend in reducing ventilator free days and 28-day mortality.

Biotest Announces Termination of Tregalizumab Collaboration with AbbVie

Biotest AG and AbbVie Inc. have terminated their collaboration for the development and commercialization of Tregalizumab, which is intended for treatment of rheumatoid arthritis, or RA. AbbVie has exercised its rights to opt-out of the worldwide license, development and commercialisation agreement signed in June 2011. Upon the effective date of termination, AbbVie will return all rights granted under the agreement at no cost to Biotest. Tregalizumab is an investigational humanised anti-CD4 monoclonal antibody, inducing selective activation of regulatory T-cells. As announced on April 24, 2015, the Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with moderate to severe rheumatoid arthritis (RA) did not meet its primary endpoint.

Biotest's IgM Concentrate Shows Encouraging Results in Life-Threatening Pneumonia

Biotest announced results of the phase II trial with IgM Concentrate (IgM enriched immunoglobulin preparation). The randomized, double-blind, placebo-controlled phase II trial was performed in 160 hospitalised patients with severe community acquired pneumonia (sCAP), a condition that has a high potential of developing into a sepsis. This patient population has a high mortality rate and comprises severely ill patients which are in need of intensive care. The study was conducted in Germany, Spain and UK. After consulting experts and authorities, Biotest has chosen a new approach by using ventilator free days (VFDs) as primary endpoint taking into consideration that the relatively small sample size would not suffice to show significant differences in mortality. Therefore, 28-day mortality was selected as one of the secondary endpoints as recommended by the sepsis guideline of the European Medical Agency (EMA). The mortality rate in this indication is high, depending on age and treatment conditions. The severity of the disease in the treated patients was confirmed by validated disease severity scores. The treatment with IgM Concentrate showed a trend in reducing ventilator free days and 28-day mortality. While the study results were not statistically significant, the observation of a 20% relative reduction in mortality rate is encouraging, keeping in mind the low patient number in this trial and the known high failure rate with other investigational compounds in sepsis-like indications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:GR €26.82 EUR -0.245

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIO.
View Industry Companies
 

Industry Analysis

BIO

Industry Average

Valuation BIO Industry Range
Price/Earnings 66.0x
Price/Sales 1.7x
Price/Book 2.0x
Price/Cash Flow 33.3x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTEST AG, please visit www.biotest.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.